ReviewCurrent rheumatology reports2013
Animal models of scleroderma: current state and recent development.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.Rheumatology (Oxford, England) · 2024Review
- Evaluation of renal damage in a bleomycin-induced murine model of systemic sclerosis.Iranian journal of basic medical sciences · 2023Article
- Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.Frontiers in cell and developmental biology · 2023Review
- Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- B cells in systemic sclerosis: from pathophysiology to treatment.Clinical rheumatology · 2021Review
- Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives.Cell regeneration (London, England) · 2020Review
- Pathogenesis of systemic sclerosis associated interstitial lung disease.Journal of scleroderma and related disorders · 2020Article
- Liver damage in bleomycin-induced pulmonary fibrosis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Transforming growth factor-β signaling in systemic sclerosis.Journal of biomedical research · 2018Article
- Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.American journal of physiology. Lung cellular and molecular physiology · 2017Article
- A high-throughput sequence analysis of Japanese patients revealed 11 candidate genes associated with type 1 autoimmune pancreatitis susceptibility.Biochemistry and biophysics reports · 2016Article
- Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.Current rheumatology reports · 2016Review
- Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?Arthritis & rheumatology (Hoboken, N.J.) · 2014Review
- MMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by three cardinal features: immunological abnormalities, vasculopathy, and fibrosis of skin and certain internal organs. Although several animal models recapitulating selected aspects of SSc have been reported, the absence of models fulfilling the full clinical picture of SSc has hindered progress in the development and testing of therapy for this disease. In recent years, three new inducible animal models have revealed the critical importance of reactive oxygen species, angiotensin II, and the combination of DNA topoisomerase I immunization and IL-6 induction in fibrosis of SSc. In addition, two genetic animal models have revealed the potential involvement of transcription factors, Fra-2 and Fli1, in the fibrosis and vasculopathy of SSc. These new animal models provide important insights into specific pathological processes of SSc and novel therapeutic targets that may lead to more effective treatment of this incurable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.